Naltrexone for the management of alcohol dependence

被引:118
作者
Anton, Raymond F. [1 ,2 ]
机构
[1] Med Univ S Carolina, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA
关键词
D O I
10.1056/NEJMct0801733
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 44- year-old businessman with a history of hypertension presents for evaluation with a report of being under stress at work and home, which has led to "unsatisfactory" sleep. Although there is some despondency, screening for depression is negative. His blood pressure is 158/ 98 mm Hg. Laboratory results include a mean corpuscular volume of 102 fl ( normal range, 80 to 100), an alanine aminotransferase level of 60 U per liter ( normal range, 7 to 41), an aspartate aminotransferase level of 45 U per liter ( normal range, 12 to 38), and a gamma-glutamyltransferase level of 110 U per liter ( normal range, 9 to 58). His physician asks about alcohol consumption, and the patient admits that perhaps he drinks "more than he should," since he often wakes up with a hangover and arrives late to work. After weekend golf outings, he comes home intoxicated, leading to arguments with his wife and embarrassment in front of his children. He has been quietly wondering about the need to cut down or stop drinking and wants some advice. His physician discusses medication or a referral to an alcohol clinic for further evaluation. Naltrexone is proposed as a treatment option.
引用
收藏
页码:715 / 721
页数:7
相关论文
共 53 条
[1]   Combined pharmacotherapies and behavioral interventions for alcohol dependence - The COMBINE study: A randomized controlled trial [J].
Anton, RF ;
O'Malley, SS ;
Ciraulo, DA ;
Cisler, RA ;
Couper, D ;
Donovan, DM ;
Gastfriend, DR ;
Hosking, JD ;
Johnson, BA ;
LoCastro, JS ;
Longabaugh, R ;
Mason, BJ ;
Mattson, ME ;
Miller, WR ;
Pettinati, HM ;
Randall, CL ;
Swift, R ;
Weiss, RD ;
Williams, LD ;
Zweben, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (17) :2003-2017
[2]   Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking [J].
Anton, RF ;
Drobes, DJ ;
Voronin, K ;
Durazo-Avizu, R ;
Moak, D .
PSYCHOPHARMACOLOGY, 2004, 173 (1-2) :32-40
[3]   Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism [J].
Anton, RF ;
Moak, DH ;
Latham, PK ;
Waid, LR ;
Malcolm, RJ ;
Dias, JK ;
Roberts, JS .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (01) :72-77
[4]  
Anton RF, 1999, AM J PSYCHIAT, V156, P1758
[5]   NALTREXONE REVERSES ETHANOL-INDUCED DOPAMINE RELEASE IN THE NUCLEUS-ACCUMBENS IN AWAKE, FREELY MOVING RATS [J].
BENJAMIN, D ;
GRANT, ER ;
POHORECKY, LA .
BRAIN RESEARCH, 1993, 621 (01) :137-140
[6]   Treatment of alcohol abuse:: An evidence-based review [J].
Berglund, M ;
Thelander, S ;
Salaspuro, M ;
Franck, J ;
Andréasson, S ;
Öjehagen, A .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2003, 27 (10) :1645-1656
[7]  
Bouza C, 2005, ADDICTION, V100, P573
[8]   Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence:: a systematic review [J].
Carmen, B ;
Angeles, M ;
Ana, M ;
María, AJ .
ADDICTION, 2004, 99 (07) :811-828
[9]   Integrating psychotherapy and pharmacotherapy to improve drug abuse outcomes [J].
Carroll, KM .
ADDICTIVE BEHAVIORS, 1997, 22 (02) :233-245
[10]  
Croop RS, 1997, ARCH GEN PSYCHIAT, V54, P1130